Gauld SB, Jacquet S, Gauvin D, et al. Inhibition of interleukin-23-mediated inflammation with a novel small molecule inverse agonist of RORγt. J Pharmacol Exp Ther. 2019;371(1):208-218.
George DM, Breinlinger EC, Friedman M, et al. Discovery of selective and orally bioavailable protein kinase Cθ (PKCθ) inhibitors from a fragment hit. J Med Chem. 2015;58(1):222−236.
Watterson SH, Xiao Z, Dodd DS, et al. Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)nicotinic acid (BMS-688521). J Med Chem. 2010;53(9):3814-3830.
Dominique Potin, Ph.D.
Dominique Potin is a senior group leader working within the medicinal chemistry team in the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard, working under the direction of Florence Wagner. He leads a group of medicinal chemists mostly looking at new drugs for cancer treatment. His focus is to help the team in the design of innovative drug-like compounds through the right combination of making improvements to their biological activity and their pharmacokinetic profile.
Potin joined the Broad Institute in November 2019 from a post as principal scientist in medicinal chemistry at Inventiva Pharma, Daix, France. He had previously held positions at Laboratoires Fournier, France (Abbott group), Eurofins-CEREP (France), and Laboratoires UPSA, France (BMS group). During his past career, Potin has been involved in a wide range of therapeutic areas including oncology, pain, inflammation, cardiovascular diseases, cardiometabolic disorders, and immuno-inflammation, through different types of targets including CNS targets, GPCRs, kinases, PPI interactions, and nuclear receptors. He is co-inventor of 13 patents and is at the origin of three clinical candidates.
Potin holds a Ph.D. from the University of Paris VI with Professor Jean d’Angelo on development of new chiral auxiliaries for asymmetric hydrogenations, as well as a master’s degree in organic chemistry from ESPCI Paris Tech. He completed his postdoctoral research at MIT with Prof Julius Rebek, Jr. on enantioselective protonations.
Contact Dominique Potin via email at firstname.lastname@example.org.